@2024 Afarand., IRAN
ISSN: 2383-3483 Journal of Police Medicine 2018;7(4):161-165
ISSN: 2383-3483 Journal of Police Medicine 2018;7(4):161-165
Relationship of Serum Visfatin Level in Obese Individuals with Insulin and Body Mass Index
ARTICLE INFO
Article Type
Original ResearchAuthors
Papi M. (1)Nezhadali M. (*)
Alinezhad (2)
(*) Department of Biology, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran
(1) Department of Biology, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran
(2) Department of Medical, Tehran Medical Branch, Islamic Azad University, Tehran, Iran
Correspondence
Address: Islamshahr Branch, Islamic Azad University, Tehran, IranPhone: -
Fax: -
ma_nejadali@yahoo.com
Article History
Received: July 1, 2018Accepted: September 11, 2018
ePublished: September 29, 2018
ABSTRACT
Aims
Obesity is a major public health problem in developed and even in developing countries worldwide. Visfatin is a protein secreted by the visceral fat tissue that regulates insulin sensitivity. It seems to modulate insulin sensitivity and appear to play an important role in the pathogenesis of insulin resistance, diabetes, dyslipidemia and obesity. The aim of this study was to determine visfatin serum concentration in overweight/obese subjects and its relationship with obesity and insulin resistance.
Materials & Methods This case-control study was performed on 93 individuals with BMI≥25 as case group, and 80 individuals with BMI<25 as control group in Military Hospital in Tehran. Anthropometric measures and metabolic parameters were obtained. Fasting insulin and visfatin were measured, using the Mercodia ELISA kit. The data were analyzed by SPSS 19 software.
Findings Plasma visfatin levels fasting glucose, insulin, insulin resistance were significantly higher in obese subjects compared to the control group (p<0.05). Also, there was a significant relationship between serum visfatin level and body mass index (BMI) and fasting blood glucose in group with BMI≥25. No relationship was found between visfatin and insulin resistance (p=0.05).
Conclusion Visfatin is associated with BMI and impaired metabolism glucose, but not with insulin resistance.
Materials & Methods This case-control study was performed on 93 individuals with BMI≥25 as case group, and 80 individuals with BMI<25 as control group in Military Hospital in Tehran. Anthropometric measures and metabolic parameters were obtained. Fasting insulin and visfatin were measured, using the Mercodia ELISA kit. The data were analyzed by SPSS 19 software.
Findings Plasma visfatin levels fasting glucose, insulin, insulin resistance were significantly higher in obese subjects compared to the control group (p<0.05). Also, there was a significant relationship between serum visfatin level and body mass index (BMI) and fasting blood glucose in group with BMI≥25. No relationship was found between visfatin and insulin resistance (p=0.05).
Conclusion Visfatin is associated with BMI and impaired metabolism glucose, but not with insulin resistance.
CITATION LINKS
[1]Mandal A. Study of prevalence of type 2 diabetes mellitus and hypertension in overweight and obese people. J Family Med Prim Care. 2014;3(1):25-8.
[2]Jafari-Adli S, Jouyandeh Z, Qorbani M, Soroush A, Larijani B, Hasani-Ranjbar S. Prevalence of obesity and overweight in adults and children in Iran: A systematic review. J Diabetes Metab Disord. 2014;13(1):121.
[3]Ng M,Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis. Lancet. 2014;384(9945):766-81.
[4] Nikooyeh B, Abdollahi Z, Salehi F, Nourisaeidlou S, Hajifaraji M, Zahedirad M, et al. Prevalence of obesity and overweight and its associated factors in urban adults from West Azerbaijan, Iran: The National Food and Nutritional Surveillance Program (NFNSP). Nutr Food Sci Res. 2016;3(2):21-6.
[5]Rashidi A, Mohammadpour-Ahranjani B, Vafa MR, Karandish M. Prevalence of obesity in Iran. Obes Rev. 2005;6(3):191-2.
[6]García-Hermoso A, Ceballos-Ceballos RJ, Poblete-Aro CE, Hackney AC, Mota J , Ramírez-Vélez R. Exercise, adipokines and pediatric obesity: A meta-analysis of randomized controlled trials. Int J Obes. 2017;41(4):475-82.
[7] El-Shafey EM, El-Naggar GF, Al-Bedewy MM, El-Sorogy H. Is there a relationship between visfatin level and type 2 diabetes mellitus in obese and non obese patients?. J Diabetes Metab. 2012;S:11.
[8]Tarik Numan A, Al-Joda AM, Kadom Jawad N. Relationship between serum visfatin and obesity in lead-exposed obese subjects and patients with osteoarthritis. Health. 2016;8:318-24.
[9]Davutoglu M, Ozkaya M, Guler E, Garipardıc M , Gursoy H, Karabiber H,and et al. Plasma visfatin concentrations in childhood obesity: Relationships with insulin resistance and anthropometric indices. Swiss Med Wkly. 2009;139(1-2):22-7.
[10]Baltaci D, Tuncel MC, Cetinkaya M, Gunduz MT, Ozbey Z, Admis O, et al. Evaluation of visfatin in patients with obesity, metabolic syndrome, insulin resistance and impaired glucose tolerance&59: Case-control study. Acta Med Anatol. 2016;4(2):61-7.
[11]Kamińska A, Kopczyńska E, Bieliński M, Borkowska A, Junik R. Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders. Endokrynol Pol. 2015;66(2):108-13.
[12]Mehdizadeh A, Hamzezadeh S, Tofighi A. Investigation of plasma visfatin changes in women with type 2 diabetes followed by endurance, resistance and combined exercise: The role of lipid profile, glycemic indices and insulin resistance. J Diabetes Metab. 2016;7(9):1000703.
[13]Ghanbarzadeh M, Omidi M. The effects of physical activity on serum visfatin level: A literature review. Int J Basic Sci Med. 2017;2(2):83-9 .
[14]Haghjooy Javanmard S, Dehghananzadeh R, Rafiee L, Naji H, Rezayat A, Sarrafzadegan N. Genetic associations of the visfatin G-948T polymorphism with obesity-related metabolic traits in an Iranian population. J Res Med Sci. 2016;21:105.
[15]Jurdana M, Petelin A, Bizjak MC, Bizjak M, Biolo G, Jenko-Pražnikar Z. Increased serum visfatin levels in obesity and its association with anthropometric/biochemical parameters, physical inactivity and nutrition. e-SPEN J. 2013;8(2):e59-67.
[16]Brema I. The relationship between plasma visfatin/nampt and type 2 diabetes, obesity, insulin resistance, and cardiovascular disease. Endocrinol Metab Int J. 2016;3(6):00068.
[17]Sharma PK, Bhansail A, Sialy R, Malhotra S, Pandhi p. Effects of piglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin endocrinol (Oxf). 2006;65(5):722-8.
[18]González-Castejón M, Rodriguez-Casado A. Dietary phytochemicals and their potential effects on obesity: A review. Pharmacol Res. 2011;64(5):438-55.
[19]Martínez Larrad MT, Corbatón Anchuelo A, Fernández Pérez C, Pérez Barba M, Lazcano Redondo Y, Serrano Ríos M, et al. Obesity and cardiovascular risk: Variations in visfatin gene can modify the obesity associated cardiovascular risk, Results from the Segovia Population Based-Study, Spain. PLoS One. 2016;11(5):e0153976.
[20]Yaturu S, Davis J, Franklin L , Shi R , Venkatesh P , Jain SK. Visfatin levels are low in subjects with type 2 diabetes compared to age-matched controls. J Diabetes Mellit. 2012;2(4):373-7.
[21]Divković D, Selthofer-Relatić K, Ćosić A, Drenjančević I, Kristek J, Radić R. Serum visfatin concentration in eutrophic and overweight/obese male children in early childhood. Periodicum Biologorum. 2014;116(2):191-6.
[22]Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005;54(10):2911-6.
[23]Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006;91(8):3165-70.
[24]Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genec H, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76(1):24-9.
[25]Fayad MH, Mohammed Abdelmeguid M, Megid A, Sayed Ahmed S, Mohy Amer Amer M. Serum visfatin, ferritin and lipid Atherogenic risk ratios as predictors of cardiovascular diseases patients. Ann med biochem sci. 2017;3(1):27-34.
[2]Jafari-Adli S, Jouyandeh Z, Qorbani M, Soroush A, Larijani B, Hasani-Ranjbar S. Prevalence of obesity and overweight in adults and children in Iran: A systematic review. J Diabetes Metab Disord. 2014;13(1):121.
[3]Ng M,Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis. Lancet. 2014;384(9945):766-81.
[4] Nikooyeh B, Abdollahi Z, Salehi F, Nourisaeidlou S, Hajifaraji M, Zahedirad M, et al. Prevalence of obesity and overweight and its associated factors in urban adults from West Azerbaijan, Iran: The National Food and Nutritional Surveillance Program (NFNSP). Nutr Food Sci Res. 2016;3(2):21-6.
[5]Rashidi A, Mohammadpour-Ahranjani B, Vafa MR, Karandish M. Prevalence of obesity in Iran. Obes Rev. 2005;6(3):191-2.
[6]García-Hermoso A, Ceballos-Ceballos RJ, Poblete-Aro CE, Hackney AC, Mota J , Ramírez-Vélez R. Exercise, adipokines and pediatric obesity: A meta-analysis of randomized controlled trials. Int J Obes. 2017;41(4):475-82.
[7] El-Shafey EM, El-Naggar GF, Al-Bedewy MM, El-Sorogy H. Is there a relationship between visfatin level and type 2 diabetes mellitus in obese and non obese patients?. J Diabetes Metab. 2012;S:11.
[8]Tarik Numan A, Al-Joda AM, Kadom Jawad N. Relationship between serum visfatin and obesity in lead-exposed obese subjects and patients with osteoarthritis. Health. 2016;8:318-24.
[9]Davutoglu M, Ozkaya M, Guler E, Garipardıc M , Gursoy H, Karabiber H,and et al. Plasma visfatin concentrations in childhood obesity: Relationships with insulin resistance and anthropometric indices. Swiss Med Wkly. 2009;139(1-2):22-7.
[10]Baltaci D, Tuncel MC, Cetinkaya M, Gunduz MT, Ozbey Z, Admis O, et al. Evaluation of visfatin in patients with obesity, metabolic syndrome, insulin resistance and impaired glucose tolerance&59: Case-control study. Acta Med Anatol. 2016;4(2):61-7.
[11]Kamińska A, Kopczyńska E, Bieliński M, Borkowska A, Junik R. Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders. Endokrynol Pol. 2015;66(2):108-13.
[12]Mehdizadeh A, Hamzezadeh S, Tofighi A. Investigation of plasma visfatin changes in women with type 2 diabetes followed by endurance, resistance and combined exercise: The role of lipid profile, glycemic indices and insulin resistance. J Diabetes Metab. 2016;7(9):1000703.
[13]Ghanbarzadeh M, Omidi M. The effects of physical activity on serum visfatin level: A literature review. Int J Basic Sci Med. 2017;2(2):83-9 .
[14]Haghjooy Javanmard S, Dehghananzadeh R, Rafiee L, Naji H, Rezayat A, Sarrafzadegan N. Genetic associations of the visfatin G-948T polymorphism with obesity-related metabolic traits in an Iranian population. J Res Med Sci. 2016;21:105.
[15]Jurdana M, Petelin A, Bizjak MC, Bizjak M, Biolo G, Jenko-Pražnikar Z. Increased serum visfatin levels in obesity and its association with anthropometric/biochemical parameters, physical inactivity and nutrition. e-SPEN J. 2013;8(2):e59-67.
[16]Brema I. The relationship between plasma visfatin/nampt and type 2 diabetes, obesity, insulin resistance, and cardiovascular disease. Endocrinol Metab Int J. 2016;3(6):00068.
[17]Sharma PK, Bhansail A, Sialy R, Malhotra S, Pandhi p. Effects of piglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin endocrinol (Oxf). 2006;65(5):722-8.
[18]González-Castejón M, Rodriguez-Casado A. Dietary phytochemicals and their potential effects on obesity: A review. Pharmacol Res. 2011;64(5):438-55.
[19]Martínez Larrad MT, Corbatón Anchuelo A, Fernández Pérez C, Pérez Barba M, Lazcano Redondo Y, Serrano Ríos M, et al. Obesity and cardiovascular risk: Variations in visfatin gene can modify the obesity associated cardiovascular risk, Results from the Segovia Population Based-Study, Spain. PLoS One. 2016;11(5):e0153976.
[20]Yaturu S, Davis J, Franklin L , Shi R , Venkatesh P , Jain SK. Visfatin levels are low in subjects with type 2 diabetes compared to age-matched controls. J Diabetes Mellit. 2012;2(4):373-7.
[21]Divković D, Selthofer-Relatić K, Ćosić A, Drenjančević I, Kristek J, Radić R. Serum visfatin concentration in eutrophic and overweight/obese male children in early childhood. Periodicum Biologorum. 2014;116(2):191-6.
[22]Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005;54(10):2911-6.
[23]Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006;91(8):3165-70.
[24]Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genec H, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76(1):24-9.
[25]Fayad MH, Mohammed Abdelmeguid M, Megid A, Sayed Ahmed S, Mohy Amer Amer M. Serum visfatin, ferritin and lipid Atherogenic risk ratios as predictors of cardiovascular diseases patients. Ann med biochem sci. 2017;3(1):27-34.